Evolving Market Trends In The Carcinoid Tumor Industry: Advancements In Neuroendocrine Tumor Detection

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Expected Carcinoid Tumor Market Size During the Forecast Period?
In recent years, there has been a significant increase in the market size of carcinoid tumors, which is projected to expand from $1.61 billion in 2024 to $1.78 billion in 2025, boasting a compound annual growth rate (CAGR) of 10.7%. Factors contributing to this growth during the historic period include the increasing occurrence of neuroendocrine tumors, heightened awareness of uncommon cancers, advancements in the healthcare infrastructure, the prevalence of targeted therapies, and the spread of clinical trials researching novel treatment alternatives.

The market size for carcinoid tumors is projected to experience significant expansion in the upcoming years, reaching $2.65 billion by 2029 with a compound annual growth rate (CAGR) of 10.5%. The expected growth during the forecast period can be credited to an increasing demand for personalized medicine, rising emphasis on prompt detection and diagnosis, augmented use of minimally invasive procedures, extensive therapeutic research, and escalating use of molecular targeted therapies. The forecast period also sees prominent trends like the incorporation of artificial intelligence (AI) and machine learning in diagnostic procedures, a shift towards combination therapies, adoption of telemedicine and remote surveillance, a focus on patient-centric care, and cooperative research.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21127

What Are the High-Growth Segments in the Carcinoid Tumor Market?
The carcinoid tumor market covered in this report is segmented -

1) By Disease Type: Gastrointestinal Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor, Lung Neuroendocrine Tumor, Other Disease Types
2) By Treatment: Octreotide, Lanreotide, Telotristat ethyl, Capecitabine (Xeloda), 5-Fluorouracil (5-FU), Doxorubicin (Adriamycin), Etoposide (VP-16), Dacarbazine (DTIC), Streptozocin, Other Treatments
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Online Channel, Offline Channel
5) By End User: Hospital And Clinics, Academic Institutions, Research Organizations

Subsegments:
1) By Gastrointestinal Neuroendocrine Tumor: Small Bowel Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors, Appendiceal Neuroendocrine Tumors
2) By Pancreatic Neuroendocrine Tumor: Insulinoma, Non-insulinoma, Glucagonoma
3) By Lung Neuroendocrine Tumor: Typical Carcinoid Tumors, Atypical Carcinoid Tumors
4) By Other Disease Types: Thymic Neuroendocrine Tumors, Ovarian Neuroendocrine Tumors

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21127&type=smp

What Key Drivers Are Expected to Influence Future Carcinoid Tumor Market Growth?
The surge in obesity is anticipated to fuel the expansion of the carcinoid tumor market in the future. An obese person is defined as someone with a body mass index (BMI) of 30 or above, which signifies an excess of body fat. The rise in obesity can be credited to reasons such as unhealthy eating habits, insufficiency of physical exercise, a passive lifestyle, and increased intake of processed and high-calorie foods. Obesity facilitates the emergence of carcinoid tumors by inducing persistent inflammation, insulin resistance, and enhanced release of growth factors that stimulate tumor progression. For example, in September 2023, the Centers for Disease Control and Prevention, a government agency in the US, reported that in 2022, adult obesity rates stood at or above 35% in 22 states, an increase from 19 states in the previous year, 2021. Thus, the escalating obesity rates are powering the growth of the carcinoid tumor market.

Which Companies Hold the Largest Share Across Different Carcinoid Tumor Market Segments?
Major companies operating in the carcinoid tumor market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Siemens Healthineers AG, Boston Scientific Corporation, Boehringer Ingelheim International GmbH, Catalent Inc, Ipsen S.A., Exelixis Inc, Novocure Limited, Hutchison MediPharma Limited (A subsidiary of HUTCHMED), Tarveda Therapeutics Inc., Lexicon Pharmaceuticals Inc., Dauntless Pharmaceuticals Inc.

What Trends Are Expected to Dominate the Carcinoid Tumor Market in the Next 5 Years?
Leading firms active in the carcinoid tumor market are channeling their efforts towards the progression of diagnostic technologies like the fully automated chromogranin A test to improve early detection and treatment outcomes. The fully automated chromogranin A (CgA) test, a diagnostic instrument used to determine chromogranin A levels, a frequently found biomarker linked with neuroendocrine tumors inclusive of carcinoid tumors. In October 2023, for example, Thermo Fisher Scientific Inc., a biotechnology research firm based in the US, was granted FDA clearance for its Thermo Scientific B·R·A·H·M·S CgA II KRYPTOR immunoassay. This was the first Chromogranin A (CgA) test to be approved by the FDA and remains the only automated immunoassay worldwide for tracking tumor progression in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients. The assay is crafted to determine CgA concentration in human serum, enabling labs and cancer centers to monitor tumor growth and gauge the effectiveness of treatments. It boosts lab productivity and ensures more precise result analysis by substituting manual lab-developed tests. The test is run on the Thermo Scientific B·R·A·H·M·S KRYPTOR compact PLUS random-access immunoassay analyzer and employs TRACE technology to yield accurate results in less than 30 minutes.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/carcinoid-tumor-global-market-report

What Are the Emerging Geographies for The Carcinoid Tumor Market Growth?
North America was the largest region in the carcinoid tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carcinoid tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Carcinoid Tumor Market?
2. What is the CAGR expected in the Carcinoid Tumor Market?
3. What Are the Key Innovations Transforming the Carcinoid Tumor Industry?
4. Which Region Is Leading the Carcinoid Tumor Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.